Meet our Accelerator, Ingela Hallberg, MD, with 25+ years across AstraZeneca, Bayer, and IQVIA. She discusses the biggest challenges for Nordic companies, from early clinical planning to reimbursement strategies.

Discover her vision for how the Nordics can stay at the forefront of global innovation.

In our conversation with Johan Bloom, CEO of Curus and experienced healthtech investor, we unpack the psychology of investor indecision, from fear of missing out to complex decision chains. He shares actionable insights on how founders can manage expectations, maintain momentum, and build trust throughout the fundraising journey.

In today’s tough funding climate, many biotech founders find themselves waiting endlessly for investor replies that never come. But knowing when to move on and how to keep momentum can make all the difference.

We introduce Jonas Ekstrand—a scientist, entrepreneur, and ecosystem builder with more than three decades of experience in life science. From pioneering cancer research to leading SwedenBIO and co-founding Nordic Life Science Days, he has dedicated his career to advancing collaboration and strengthening the Nordic region’s global presence. He shares his reflections on building a multifaceted career, the mentors who inspired him, and the untapped potential of the Nordic life science ecosystem.

Cell & Gene Therapy Insights recently published an article by Helena Strigård, Founder of Ventures Accelerated, exploring the untapped medical and market potential in women’s health and the transformative role of AI and precision medicine. 

In conversations with Roger Lias and Maria Lundius, we found that the Nordics are a strategic entry point into Europe for life sciences, combining faster clinical trials, high-quality data, strong biomanufacturing capacity, and a uniquely collaborative culture that accelerates development and de-risks scale-up.

FDA’s recent move to waive requirements for clinical efficacy studies (CESs) to approve of monoclonal antibody biosimilars certainly redefines the regulatory landscape for biologic drugs. This decision opens the door to new strategies and players in the biosimilars sector. The impact of FDA’s new approval policy is thus potentially very significant, promising lower development costs, faster patient access, and certainly enhanced competition, particularly benefiting generic and biotech firms. 

Learn how SANC is transforming neurosurgery across Africa through visionary collaboration — and support the mission at the Impact Days gala on December 11 in Stockholm, featuring global leaders turning bold ideas into lasting impact.

Facing $300 billion in lost revenue from expiring patents, Big Pharma is turning to M&A to secure future growth — triggering a wave of dealmaking across the Biotech sector. Major players are snapping up companies in high-value areas like oncology, neuroscience, and AI-enabled platforms. While this creates valuable exit opportunities for mature Biotechs, early-stage innovators may struggle as buyers focus on de-risked assets. To stand out in this climate, Biotech firms need sharp, targeted partnering strategies.

We introduce Andreas Hallbert— a branding strategist working at the crossroads of design, business, and life science. He shares how simplicity, clarity, and strong visual storytelling help even small companies build trust, stand out, and communicate their innovation effectively.

Noviral, a frontrunner in preventive healthcare solutions, announced the appointment of Mattias Bodin as the company’s new interim Chief Executive Officer (CEO). With over 30 years of experience in the pharmaceutical and medical device industries, Mattias is poised to steer Noviral into its next phase of growth and innovation, while fully backed by Ventures Accelerated - a consortium of C-suite leaders in life sciences.

As the field of Advanced Therapy Medicinal Products (ATMPs) faces mounting regulatory, financial, and scientific pressures, companies are taking a moment to pause, recalibrate, and return to execution fundamentals. This article explores how collaboration, early-stage funding, and scalable innovation are essential to ensure the continued success of next-generation therapies like cell and gene treatments.